Anthony Filippis, BSc(Hons) PhD, MBA – Founder & Executive Director
Anthony is an experienced biotechnology business executive with deep understanding and knowledge of the international biotechnology, pharmaceutical and life sciences industries. In addition to his role at Senz Oncology Pty Ltd, Anthony is a Co-founder of Afandin Pty Ltd, a technology-focussed corporate advisory company, concentrating on the biotechnology, pharmaceutical and life sciences industries. Anthony has held a number of senior executive positions and has worked in a variety of CEO, operational, business development, corporate development, strategic and executive management roles within ASX-listed and private companies. His career spans a number of technology areas, including therapeutics, diagnostics, medical devices, healthcare & health IT, life sciences, agriculture and consulting. Anthony received his PhD in biochemistry from the University of Melbourne and his MBA from LaTrobe University, specialising in entrepreneurship & innovation and new venture creation. He currently serves as a Director on the Board of Neurevest Ltd, MingSight Pharmaceuticals Pty Ltd and Boulder Ionics Pty Ltd.
Ian Nisbet, PhD – Founder and Executive Director
Ian has over 30 years of drug development, business development and general management experience in the Australian and international biotechnology sector. In addition to his role at Senz Oncology, Ian is also a Co-founder and Partner in the biotechnology consulting company Afandin Pty Ltd. He has previously been CEO/MD of Xenome Ltd and Meditech Research Ltd and held senior management positions at Millennium Pharmaceuticals Inc, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian has a part-time appointment as Deputy Director (Commercialisation) at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland. He currently serves as Chairman of Verva Pharmaceuticals Ltd and vivoPharm Pty Ltd; and is a non-Executive Director of Velacor Pty Ltd, Solagran Ltd, ACYTE Biotech Pty Ltd, Cerulean Pharmaceuticals Pty Ltd and Tunitas Therapeutics Australia Pty Ltd.
Dennis M Brown, PhD – Non Executive Director
Dennis has more than 20 years of drug discovery and development experience. In addition to his role at Senz Oncology, Dennis is the Founder and President of Valent Technologies, LLC and Co-founder, Chief Scientific Officer and a Director of DelMar Pharmaceuticals. In 1999, he founded ChemGenex Pharmaceuticals, of which he served as President and a Director until 2009. He was previously a Co-founder of Matrix Pharmaceuticals where he served as Vice President (VP) of Scientific Affairs from 1985-1995 and as VP, Discovery Research, from 1995-1999. He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in radiology at Stanford University Medical School. He received his B.A. in biology and chemistry, M.S. in cell biology and PhD in radiation and cancer biology, all from New York University. Dennis is an inventor on approximately 34 issued US patents and applications, many with foreign counterparts.